Novamigra
Therapeutics
a pioneering biopharmaceutical company developing a best-in-class novel therapy for migraine prophylaxis
Novamigra
Therapeutics
a pioneering biopharmaceutical company developing a best-in-class novel therapy for migraine prophylaxis
Data confirmed derisked clinical development
Data confirmed derisked clinical development
Data confirmed derisked clinical development
Enter first-in-human trial in Q3 2026
Enter first-in-human trial in Q3 2026
Enter first-in-human trial in Q3 2026
Novel mechanism of action
Novel mechanism of action
Novel mechanism of action
Targeting around 50% of resistant patients
Targeting around 50% of resistant patients
Targeting around 50% of resistant patients
High unmet medical need in migraine therapy
Migraine impacts ca. 1 billion patients worldwide, out of which ~40% should be treated prophylactically.
The global market size for migraine prophylaxis is expected to reach 10 billion USD by 2027 according to Nature Reviews
Migraine impacts ca. 1 billion patients worldwide, out of which ~40% should be treated prophylactically.
The global market size for migraine prophylaxis is expected to reach 10 billion USD by 2027 according to Nature Reviews
Migraine impacts ca. 1 billion patients worldwide, out of which ~40% should be treated prophylactically.
The global market size for migraine prophylaxis is expected to reach 10 billion USD by 2027 according to Nature Reviews
Migraine impacts ca. 1 billion patients worldwide, out of which ~40% should be treated prophylactically.
The global market size for migraine prophylaxis is expected to reach 10 billion USD by 2027 according to Nature Reviews
Tamás Kökény
Tamás Kökény
Zalán Péterfi MD PhD
Zalán Péterfi MD PhD
Sándor Farkas MD PhD
Sándor Farkas MD PhD
Natalia Novac PhD
Natalia Novac PhD
Marc Debelle MD PhD
Marc Debelle MD PhD
Gábor Fodor-Papp
Gábor Fodor-Papp
Strong leadership with impressive track record
Strong leadership with impressive track record
Strong leadership with impressive track record
Novamigra prides itself with 90+ years of Pharma R&D experience and multiple assets taken to clinical phase by its team members
Novamigra prides itself with 90+ years of Pharma R&D experience and multiple assets taken to clinical phase by its team members
The Novamigra team brings over 100 years of combined pharmaceutical R&D experience, having successfully advanced 10 assets to the clinical phase and brought 2 to market.
Tamás Kökény
Zalán Péterfi MD PhD
Sándor Farkas MD PhD
Natalia Novac PhD
Marc Debelle MD PhD
Gábor Fodor-Papp
Tamás Kökény
Zalán Péterfi MD PhD
Sándor Farkas MD PhD
Natalia Novac PhD
Marc Debelle MD PhD
Gábor Fodor-Papp
Tamás Kökény
Zalán Péterfi MD PhD
Sándor Farkas MD PhD
Natalia Novac PhD
Marc Debelle MD PhD
Gábor Fodor-Papp
Tamás Kökény
Zalán Péterfi MD PhD
Sándor Farkas MD PhD
Natalia Novac PhD
Marc Debelle MD PhD
Gábor Fodor-Papp
Latest update
Novamigra Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Novamigra Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Novamigra Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Novamigra Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145
Novamigra Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145